Thanx for the insights Mac--I hadnt seen it when I put my last post so it had no bearing on why I put it--still food for thought
Printable View
Thanx for the insights Mac--I hadnt seen it when I put my last post so it had no bearing on why I put it--still food for thought
When, next month are the US sales figures due?
I guess ,like any company it will depend on whether they are impressive .
I wont make any decisions until this potentially market affecting US Govt. situation gets worked out though.
Thanks for all the info. from both of you Cheers
I don’t think the HY reporting date has been announced, but it has been the last week in November over the last couple of years.
Skid, with some caution we can't expect more sales in HY14 than can have possibly been achieved. PEB have a commercialisation plan and are on schedule against it.
US sales commenced on 1st July providing only a 3 month contribution within the reporting period. With the risk of repeating the discussion earlier in the thread, the sales staff are in training at this time. Based on growth in NZ I speculate that 200 US sales would be a good result.
Having said that revenues should be up on the FY13 result by a healthy percentage, maybe even double digit growth.
I'll be a lot more interested in reported progress in terms of approaches to health organisations and numerical sales guidance toward FY14. Sales ramp up in earnest should be in the second half.
Still trending down
Announcement this week did nothing for share price - that must have been a disappointment for them
Probably have to wait another week or two before the next announcement - need something to give the share price a boost - seems to be their modus operandi lately
Waiting for another trade here
http://www.cxbladder.com/for-healthc...illing-policy/
"Pacific Edge is a Medicare provider. Pacific Edge will accept patients with Medicare coverage, and these patients will have no financial responsibility for Cxbladder"
[QUOTE=Hancocks;431182]Hi Skid, very interesting documentary, thanks for the link. Sadly it is an indictment on mankind as a whole. Perhaps we think that mankind is civilised, when in actual fact we have just learned to pretend to suppress our selfish greedy ways and don’t perform certain body functions in front of others. We are still just hunter gatherers, but I suppose we have at least added a few so called niceties to our foraging. Pierce the skin of mankind and there is still a naked roaring ape inside; but, he may still need diagnosis or monitoring for bladder cancer.
:D[/QUOTE
Absolutely,and I say again,I also believe its a good product--but my point was that all those people also needed to be told their kids were drinking milk that was at risk of possibly causing them harm.
It was simply to not underestimate big powerful corporations.--But I realize its a very hard thing to factor in to an investment decision,other than to be aware there are things that can derail a good product .
Its just in response to some of the ''its all up from here-massively''comments.
Just trying to keep my feet on the ground(and i suppose play devil advocate)
Has anyone done any research on what changes Obama care will have on the health system?
Would PEB comment on that sort of thing?
Is it possible that it is going to come down to who is best at negotiating a contract with this massive gov insurance provider?
Im just bringing this all up because some of you are particularly good at researching and information gathering on this thread.
We each need to do our own research, although I’d be the first to say that PEB don’t help us by not providing much in the way of guidance.
Post capital raising, growth stocks can remain undervalued for long periods of time proportionally reflecting the magnitude of risk associated with the stock. As risk gradually falls away the SP gradually approaches fundamental valuation.
My view is that PEB has de-risked substantially over the last 12 months, yet the SP has not yet stepped up toward fundamental (DCF) valuation. This may be due to no analysts yet covering the stock, traders keeping the stock range bound, and the market simply just awaiting the formal announcement that US sales have commenced.
Revenues at HY13 were $325k, since then PEB have entered the US market and gained further confidence in the local market with CLIA approvals, user studies being completed, first DHB being signed up, etc. At HY14 I’m looking for around $550k as being a very good result (+69%).
I’m happy to share and test views, let us know what conclusion you come to.
I'm bowing to your greater knowledge but, on the one hand, you say many have tried and none have succeeded so why do you think PEB have what it takes? Is it good business vision, a gut feel or what?
Disc. holder of PEB, DIL and a few others I'd rather not mention :cool:
Thanks for the summary of your position with PEB.
I think they are an exciting, well managed company and offer amazing returns if things go to plan. By their own admission they may face many issues in the next few years but the market appears to be theirs to take.
Just depends on the medical communities uptake of the new product plus the other products in the pipeline – no pun intended.